Award

European Vascular Interventions and Therapeutic Innovation Network

Description: EVOluTION, a pioneering network within EU in view of its focus on endogenous protective mechanisms, is formed to provide training for 11 young researchers in innovative therapeutic strategies, integrating early detection and prevention, to yield novel approaches to the management of chronic vascular and metabolic diseases that affect the increasing ageing population of Western societies. Fully aligned with the knowledge triangle (business, research and higher education) platform being developed at the EU level, EVOluTION-trained young scientists will gain valuable knowledge and multidisciplinary skills: only interdisciplinary and cross-cutting research can lead to novel therapeutic tools and scientific angles to address these challenging medical, societal and industrial issues. EVOluTION provides a conducive structure by bringing 5 leading academic institutions and 1 SME, together with 6 Pharma and biotech companies, 1 Policy-maker, and 1 Patent & Trade firm as Partner Organisations, from 6 EU countries. The science of EVOluTION evolves around the innovative concept of boosting natural protective mechanisms operating in our body, focusing on the vasculature, to answer 3 key questions: Can we exploit mediators and targets of endogenous tissue protection? Can we exploit these pathways to yield innovative therapeutic strategies? Can dietary approaches boost these endogenous protective processes? The Network Partners guarantee delivery of training through knowledge creation, knowledge exploitation and knowledge communication. Scientific and educational expertise of the partners, leaders in areas like computational chemistry, nutraceuticals, resolution pharmacology and vascular therapies will be maximally exploited. The EVOluTION training platform is based on state-of-the-art lab-based and network-wide and local training activities, including secondments and scientific visits and specialized transferable skills focussed in entrepreneurship and societal engagement.
Amount: €2,887,000
Funding type: fellowship
Funder scheme: H2020 - MSCA-ITN-ETN
Start date: 2016-04-01
End date: 2020-03-31
Institution: QUEEN MARY UNIVERSITY OF LONDON
Funded outputs count: 26
Funder award ID: 675111
OpenAlex ID: G7332950818
2025 · Nicki Dyson, Rayomand S. Khambata, et al. · Redox Biology · 3
2023 · Jan Nagenborg, Han Jin, et al. · Frontiers in Immunology · 22
2022 · Angelina Pavlic, Nasim Bahram Sangani, et al. · International Journal of Molecular Sciences · 16
2021 · Monika Maciuszek, Almudena Ortega-Gomez, et al. · European Journal of Medicinal Chemistry · 4
2021 · Harriet E. Allan, Melissa A. Hayman, et al. · Journal of Thrombosis and Haemostasis · 59
2021 · Daniëlle M. Coenen, Alexandra C. A. Heinzmann, et al. · Cells · 14
2020 · Asim Cengiz Akbulut, Angelina Pavlic, et al. · Nutrients · 72
2020 · Alexandru Florea, Agnieszka Morgenroth, et al. · European Journal of Preventive Cardiology · 12
2019 · Silvia Oggero, Shani Austin-Williams, et al. · Frontiers in Pharmacology · 85
2019 · Bartolo Ferraro, Giovanna Leoni, et al. · Journal of the American College of Cardiology · 194
2019 · Ploingarm Petsophonsakul, Malgorzata Furmanik, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 343
2019 · Maurice Halder, Ploingarm Petsophonsakul, et al. · International Journal of Molecular Sciences · 256
2019 · Kristof Van Avondt, Lars Maegdefessel, et al. · Thrombosis and Haemostasis · 55
2018 · Sanne L. Maas, Oliver Soehnlein, et al. · Frontiers in Immunology · 136
2018 · Nicole Paulin, Joana R. Viola, et al. · Circulation · 107
2018 · Carla Winter, Carlos Silvestre-Roig, et al. · Cell Metabolism · 195
2018 · Marilena Crescente, Laura Menke, et al. · British Journal of Pharmacology · 70
Year
Topic